Mar 23 2010
Ongoing follow up of the surviving patients from the phase I study of
ADXS11-001 for the treatment of cervix cancer failures conducted by Advaxis,
Inc., (OTCBB: ADXS), the live, attenuated Listeria
monocytogenes (Listeria) immunotherapy company, has shown
that two (2) of fifteen (15) treated patients or 13.3% are still alive
1,248 and 1,128 days after receiving their initial dose.
This result of 13.3% of treated patients alive at over three (3) years,
post dosing, exceeds the-established historical finding that the
one-year survival for these patients is approximately 5% irrespective of
the treatment regimen administered. The one-year survival in the Advaxis
trial was 53%. Similarly, once progression begins following a failure of
prior cytotoxic treatment the median survival for these patients is 180
days as compared with 347 days in the Advaxis study.
More information on this clinical trial can be found in the published
results of this trial (Vaccine 27
2009 3975–3983).
Study unveils novel bladder cancer diagnostic model based on key mitochondrial genes